Comparison of autologous hematopoietic cell transplantation performed in tandem and in disease relapse in multiple myeloma patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F18%3A10380145" target="_blank" >RIV/00669806:_____/18:10380145 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.elis.sk/download_file.php?product_id=5712&session_id=jh1b5035l8fc5lm7jbsia8kso7" target="_blank" >http://www.elis.sk/download_file.php?product_id=5712&session_id=jh1b5035l8fc5lm7jbsia8kso7</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.4149/neo_2018_170511N346" target="_blank" >10.4149/neo_2018_170511N346</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Comparison of autologous hematopoietic cell transplantation performed in tandem and in disease relapse in multiple myeloma patients

Popis výsledku v původním jazyce

Multiple myeloma is a malignant hemato-oncological malignancy that affects up to 600 people in the Czech Republic every year. Treatment options are under constant improvement and the autologous hematopoietic cell transplantation (Tx) remains a part of treatment protocols. Despite modern drug administration, the autologous Tx keeps its irreplaceable position and when ensuring two autologous Tx, the studies confirm a survival time that is more than twice as long as in nontransplant patients. However, there are no standardized procedures specifying the period in between the transplantations in more details. Within our group, we compared the total of 66 patients who were administered a double transplant. One group underwent both planned tandem autologous Tx within a median of six months while mostly reaching just a partial remission (PR) and less after the first transplant and out of disease progression. The other group of patients only underwent the second Tx within a median of up to 14 months during a progression period or disease relapse. Both groups were comparable as far as basic parameters are concerned (age, type of induction therapy, cytogenetic risk). A significantly better TFS (treatment free survival) and overall survival (OS) were observed in the group where a tandem Tx was administered. TFS was 18 months and median OS was not reached for the group of patients who received tandem Tx while TFS was 10 months (p=0.04) and median OS was 57 months (p=0.005) for those who received delayed second Tx. In the group of patients who received second Tx during relapse, we observed that TFS and OS were shorter in those with a higher paraprotein level, suggesting the potential role of paraprotein level as a prognostic marker. The TFS in the subgroup with a high initial level was 4 months vs. 11 months (p=0.0016) and OS 44 months vs. 65 months (p=0.03).

Název v anglickém jazyce

Comparison of autologous hematopoietic cell transplantation performed in tandem and in disease relapse in multiple myeloma patients

Popis výsledku anglicky

Multiple myeloma is a malignant hemato-oncological malignancy that affects up to 600 people in the Czech Republic every year. Treatment options are under constant improvement and the autologous hematopoietic cell transplantation (Tx) remains a part of treatment protocols. Despite modern drug administration, the autologous Tx keeps its irreplaceable position and when ensuring two autologous Tx, the studies confirm a survival time that is more than twice as long as in nontransplant patients. However, there are no standardized procedures specifying the period in between the transplantations in more details. Within our group, we compared the total of 66 patients who were administered a double transplant. One group underwent both planned tandem autologous Tx within a median of six months while mostly reaching just a partial remission (PR) and less after the first transplant and out of disease progression. The other group of patients only underwent the second Tx within a median of up to 14 months during a progression period or disease relapse. Both groups were comparable as far as basic parameters are concerned (age, type of induction therapy, cytogenetic risk). A significantly better TFS (treatment free survival) and overall survival (OS) were observed in the group where a tandem Tx was administered. TFS was 18 months and median OS was not reached for the group of patients who received tandem Tx while TFS was 10 months (p=0.04) and median OS was 57 months (p=0.005) for those who received delayed second Tx. In the group of patients who received second Tx during relapse, we observed that TFS and OS were shorter in those with a higher paraprotein level, suggesting the potential role of paraprotein level as a prognostic marker. The TFS in the subgroup with a high initial level was 4 months vs. 11 months (p=0.0016) and OS 44 months vs. 65 months (p=0.03).

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Neoplasma

ISSN

0028-2685

e-ISSN

—

Svazek periodika

65

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

SK - Slovenská republika

Počet stran výsledku

6

Strana od-do

952-957

Kód UT WoS článku

000455707400001

EID výsledku v databázi Scopus

2-s2.0-85057289152